Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line durvalumab with or without tremelimumab plus platinum-gemcitabine versus standard chemotherapy in unresectable locally advanced or metastatic urothelial cancer
MOH_2018-11-06_003722Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in transitional cell carcinoma (TCC) and bladder cancer comparing Durvalumab + standard of care chemotherapy, Durvalumab + tremelimumab + standard of care chemotherapy and Standard of care chemotherapy (3 arms). Primary endpoints: Progression-free survival and Overall survival. Started Oct 2018; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on MOH_2018-11-06_003722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-06_003722.